IMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasis
Conclusions These results collectively demonstrate IMB5036 can be a promising therapeutic candidate for patients with HCC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Genetics | Hepatocellular Carcinoma | Investigational New Drugs | Liver Cancer